A case of TAFRO syndrome maintained in remission for 5 years after discontinuation of tocilizumab.
Mod Rheumatol Case Rep
; 7(1): 205-210, 2023 01 03.
Article
in En
| MEDLINE
| ID: mdl-35134213
ABSTRACT
TAFRO syndrome is a subtype of idiopathic multicentric Castleman's disease (iMCD) that is characterised by thrombocytopenia, generalised oedema, fever, bone marrow fibrosis, renal failure, and organ enlargement and has a poor prognosis. The prognosis of TAFRO syndrome is worse than that of iMCD-not otherwise specified, with a high mortality rate. There are only a few long-term follow-up reports after remission of TAFRO syndrome with tocilizumab (TCZ) treatment in a patient in whom all drugs were discontinued after attaining sustained remission. Here, we report a case in which interleukin-6 negativity was confirmed and remission was maintained without relapse for 5 years after all drug treatments, including TCZ, were discontinued.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Castleman Disease
/
Renal Insufficiency
Limits:
Humans
Language:
En
Journal:
Mod Rheumatol Case Rep
Year:
2023
Document type:
Article
Affiliation country:
Japan